1 active not recruiting, 1 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Grey Wolf Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1) Part A - Single Ascending Dose (SAD) in Healthy Human Volunteers, Part B - Multiple Ascending Dose (MAD) in participants with axSpA, Part C - Safety expansion cohort in participants with axSpA - Axial Spondyloarthritis (AxSpA) | Phase 1 / Phase 2 | Recruiting | Grey Wolf Therapeutics | 140 | 2025-07-28 | 2026-09-18 |
| EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) Module 1 (GRWD5769 on its own as monotherapy), Module 2 (GRWD5769 in combination with cemiplimab, administered IV) - Advanced Solid Malignancy | Phase 1 / Phase 2 | Active not recruiting | Grey Wolf Therapeutics | 300 | 2023-05-21 | 2026-10-13 |
Axial Spondyloarthritis (1) · Carcinoma, Hepatocellular (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uterine Cervical Neoplasms (1)
Sagittal Abdominal Diameter (1) · cemiplimab (1) · mycophenolic adenine dinucleotide (1)
Australia (2) · Spain (2) · Belgium (1) · France (1) · Germany (1) · Netherlands (1) · Poland (1) · United Kingdom (1)